Skip to main content
SpringerLink
Log in

Drug Treatment of Elderly Patients with Acute Myocardial Infarction

Practical Recommendations

  • Therapy In Practice
  • Published:
Drugs & Aging Aims and scope Submit manuscript

Abstract

Aspirin (acetylsalicylic acid) should be administered to patients on day 1 of an acute myocardial infarction (MI) and continued indefinitely. Early intravenous β-blockade should be used during acute MI. β-blockers should be continued indefinitely. Angiotensin-converting enzyme (ACE) inhibitors should be used in patients with acute MI with ST-segment elevation in two or more anterior precordial leads. ACE inhibitors should be used during and after acute MI in patients with chronic heart failure (CHF) or with a left ventricular ejection fraction ≤40%. There are no class I indications for using calcium channel antagonists during and after acute MI. Intravenous heparin should be used in patients with acute MI undergoing coronary revascularisation and in patients at high risk for systemic embolisation. Enoxaparin should be used in patients with non-Q-wave MI. Thrombolytic therapy should be considered in patients with acute MI with ST-segment elevation in contiguous leads of a 12-lead electrocardiogram or with left bundle branch block. Platelet glycoprotein IIb/IIIa inhibitors should be administered intravenously as an adjunct to heparin and aspirin in patients with non-Q-wave MI. Intravenous nitroglycerin should be used: (i) for the first 24 to 48 hours in patients with acute MI and CHF, large anterior MI, persistent ischaemia or hypertension; and (ii) continued beyond 48 hours in patients with recurrent angina pectoris or persistent pulmonary congestion. Long-acting nitrates should be given after MI, along with β-blockers, to patients with angina pectoris. There are no class I indications for using intravenous magnesium during acute MI. The routine use of antiarrhythmic drugs other than β-blockers during and after acute MI is not recommended.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Table III
Table IV
Table V

Similar content being viewed by others

References

  1. Gillum RF. Trends in acute myocardial infarction and coronary heart disease death in the United States. J Am Coll Cardiol 1993; 23: 1273–7

    Article  Google Scholar 

  2. Elder AT, Fox KAA. Ischaemic heart disease in the elderly. Martin A, Camm AJ, editors. Geriatric cardiology principles and practice. Chichester: John Wiley and Sons Ltd, 1994: 333–70

    Google Scholar 

  3. Hjalmarson A, Herbiz J, Malek J, et al. Effect on mortality of metoprolol in acute myocardial infarction. Lancet 1981; II: 823–7

    Article  Google Scholar 

  4. MIAMI Trial Research Group. Metoprolol in acute myocardial infarction (MIAMI): a randomised placebo-controlled international trial. Eur Heart J 1985; 6: 199–226

    Google Scholar 

  5. ISIS-1 (First International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous atenolol among 16,027 cases of suspected acute myocardial infarction. Lancet 1986; II: 57–66

    Google Scholar 

  6. Patrano C. Aspirin as an antiplatelet drug. N Engl J Med 1994; 330: 1287–94

    Article  Google Scholar 

  7. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988; II: 349–60

    Google Scholar 

  8. Krumholz HM, Radford MJ, Ellerbeck EF, et al. Aspirin in the treatment of acute myocardial infarction in elderly Medicare beneficiaries. Patterns of use and outcomes. Circulation 1995; 92: 2841–7

    Article  PubMed  CAS  Google Scholar 

  9. Ryan TJ, Antman EM, Brooks NH, et al. 1999 update: ACC/AHA guidelines for the management of patients with acute myocardial infarction: executive summary and recommendations. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). Circulation 1999; 100: 1016–30

    Article  PubMed  CAS  Google Scholar 

  10. Smith Jr SC. Drug treatment after acute myocardial infarction: is treatment the same for the elderly as in the young patient? Am J Geriatr Cardiol 1998; 7: 60–4

    PubMed  Google Scholar 

  11. Teo KK, Yusuf S, Furberg CD. Effects of prophylactic antiarrhythmic drug therapy in acute myocardial infarction. An overview of results from randomized controlled trials. JAMA 1993; 270: 1589–95

    Article  PubMed  CAS  Google Scholar 

  12. Hansteen V. Beta blockade after myocardial infarction: the Norwegian Propranolol Study in high-risk patients. Circulation 1983; 67 (6 Pt 2): 157–60

    Google Scholar 

  13. Gundersen T, Abrahamsen AM, Kjekshus J, et al. Timolol-re-lated reduction in mortality and reinfarction in patients ages 65–75 years surviving acute myocardial infarction. Circulation 1982; 66: 1179–84

    Article  PubMed  CAS  Google Scholar 

  14. Pedersen TR, on behalf of the Norwegian Multicentre Study Group. Six-year follow-up of the Norwegian Multicentre Study on Timolol after acute myocardial infarction. N Engl J Med 1985; 313: 1055–8

    Article  PubMed  CAS  Google Scholar 

  15. Beta-Blocker Heart Attack Trial Research Group. Arandomized trial of propranolol in patients with acute myocardial infarction. JAMA 1982; 247: 1707–14

    Article  Google Scholar 

  16. Park KC, Forman DE, Wei JY. Utility of beta-blockade treatment for older postinfarction patients. J Am Geriatr Soc 1995; 43: 751–5

    PubMed  CAS  Google Scholar 

  17. Chadda K, Goldstein S, Byington R, et al. Effect of propranolol after acute myocardial infarction in patients with congestive heart failure. Circulation 1986; 73: 503–10

    Article  PubMed  CAS  Google Scholar 

  18. The Beta-Blocker Pooling Project Research Group. The Beta-Blocker Pooling Project (BBPP): subgroup findings from randomised trials in post-infarction patients. Eur Heart J 1988; 9: 8–16

    Article  Google Scholar 

  19. Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 1996; 334: 1349–55

    Article  PubMed  CAS  Google Scholar 

  20. Aronow WS, Ahn C, Kronzon I. Effect of propranolol versus no propranolol on total mortality plus nonfatal myocardial infarction in older patients with prior myocardial infarction, congestive heart failure, and left ventricular ejection fraction ≥40% treated with diuretics plus angiotensin-converting-en-zyme inhibitors. Am J Cardiol 1997; 80: 207–9

    Article  PubMed  CAS  Google Scholar 

  21. Kennedy HL, Brooks MM, Barker AH, et al. Beta-blocker therapy in the Cardiac Arrhythmia Suppression Trial. Am J Cardiol 1994; 74: 674–80

    Article  PubMed  CAS  Google Scholar 

  22. Aronow WS, Ahn C, Mercando AD, et al. Effect of propranolol versus no antiarrhythmic drug on sudden cardiac death, total cardiac death, and total death in patients ≥62 years of age with heart disease, complex ventricular arrhythmias, and left ventricular ejection fraction ≥40%. Am J Cardiol 1994; 74: 267–70

    Article  PubMed  CAS  Google Scholar 

  23. Aronow WS, Ahn C, Mercando AD, et al. Decrease of mortality by propranolol in patients with heart disease and complex ventricular arrhythmias is more an anti-ischemic than an antiarrhythmic effect. Am J Cardiol 1994; 74: 613–5

    Article  PubMed  CAS  Google Scholar 

  24. Aronow WS, Ahn C, Mercando AD, et al. Effect of propranolol on circadian variation of ventricular arrhythmias in elderly patients with heart disease and complex ventricular arrhythmias. Am J Cardiol 1995; 75: 514–6

    Article  PubMed  CAS  Google Scholar 

  25. Aronow WS, Ahn C, Mercando AD, et al. Effect of propranolol on circadian variation of myocardial ischemia in elderly patients with heart disease and complex ventricular arrhythmias. Am J Cardiol 1995; 75: 837–9

    Article  PubMed  CAS  Google Scholar 

  26. Aronow WS, Ahn C, Mercando AD, et al. Circadian variation of sudden cardiac death or fatal myocardial infarction is abolished by propranolol in patients with heart disease and complex ventricular arrhythmias. Am J Cardiol 1994; 74: 819–21

    Article  PubMed  CAS  Google Scholar 

  27. Soumerai SB, McLaughlin TJ, Spiegelman D, et al. Adverse outcomes of underuse of beta-blockers in elderly survivors of acute myocardial infarction. JAMA 1997; 277: 115–21

    Article  PubMed  CAS  Google Scholar 

  28. Yusuf S, Wittes J, Probstfield J. Evaluating effects of treatment subgroups of patients within a clinical trial: the case of non-Q-wave myocardial infarction and beta blockers. Am J Cardiol 1990; 60: 220–2

    Article  Google Scholar 

  29. Aronow WS. Postinfarction use of beta-blockers in elderly patients. Dugs Aging 1997; 6: 424–32

    Article  Google Scholar 

  30. Swedberg K, Held P, Kjekshus J, et al., on behalf of the CONSENSUS II Study Group. Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction. Results of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II). N Engl J Med 1992; 327: 678–84

    Article  PubMed  CAS  Google Scholar 

  31. Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto Miocardico. Six-month effects of early treatment with lisinopril and transdermal glyceryl trinitrate singly and together withdrawn six weeks after acute myocardial infarction: the GISSI-3 Trial. J Am Coll Cardiol 1996; 27: 337–44

    Google Scholar 

  32. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. Lancet 1995; 345: 669–85

    Article  Google Scholar 

  33. Ambrosioni E, Borghi C, Magnani B, et al. The effect of the angiotensin-converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. N Engl J Med 1995; 332: 80–5

    Article  PubMed  CAS  Google Scholar 

  34. Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the Survival and Ventricular Enlargement Trial. N Engl J Med 1992; 327: 669–77

    Article  PubMed  CAS  Google Scholar 

  35. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993; 342: 821–8

    Google Scholar 

  36. Kober L, Torp-Pedersen C, Carlsen JE, et al. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 1995; 333: 1670–6

    Article  PubMed  CAS  Google Scholar 

  37. Muller JE, Morrison J, Stone PH, et al. Nifedipine therapy for patients with threatened and acute myocardial infarction: a randomized, double-blind, placebo-controlled comparison. Circulation 1984; 69: 740–7

    Article  PubMed  CAS  Google Scholar 

  38. Wilcox RG, Hampton JR, Banks BC, et al. Trial of early nifedipine in acute myocardial infarction: the Trent study. BMJ 1986; 293: 1204–8

    Article  PubMed  CAS  Google Scholar 

  39. Yusuf S, Held P, Furberg C. Update of effects of calcium antagonists in myocardial infarction or angina in light of the second Danish Verapamil Infarction Trial (DAVIT-II) and other recent studies. Am J Cardiol 1991; 67: 1295–7

    Article  PubMed  CAS  Google Scholar 

  40. Furberg CD, Psaty BM, Meyer JV. Nifedipine: dose-related increase in mortality in patients with coronary heart disease. Circulation 1995; 92: 1326–31

    Article  PubMed  CAS  Google Scholar 

  41. The Multicenter Diltiazem Postinfarction Trial Research Group. The effect of diltiazem on mortality and reinfarction after myocardial infarction. N Engl J Med 1988; 319: 385–92

    Article  Google Scholar 

  42. Goldstein RE, Boccuzzi SJ, Cruess D, et al. Diltiazem increases late-onset congestive heart failure in postinfarction patients with early reduction in ejection fraction. Circulation 1991; 83: 52–60

    Article  PubMed  CAS  Google Scholar 

  43. Kostis JB, Lacy CR, Cosgrove NM, et al. Association of calcium channel antagonist use with increased rate of acute myocardial infarction in patients with left ventricular dysfunction. Am Heart J 1997; 133: 550–7

    Article  PubMed  CAS  Google Scholar 

  44. Bybee KA, Wright RS, Williams BA, et al. Effect of concomitant or very early statin administration on in-hospital mortality and reinfarction in patients with acute myocardial infarction. Am J Cardiol 2001; 87: 771–4

    Article  PubMed  CAS  Google Scholar 

  45. Schwartz GG, Olsson AG, Ezekowitz MD, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes. The MIRACL Study: a randomized controlled trial. JAMA 2001; 285: 1711–8

    Article  PubMed  CAS  Google Scholar 

  46. Krumholz HM, Hennen J, Ridker PM, et al. Use and effectiveness of intravenous heparin therapy for treatment of acute myocardial infarction in the elderly. J Am Coll Cardiol 1998; 31: 973–9

    Article  PubMed  CAS  Google Scholar 

  47. Rich MW Heparin for acute myocardial infarction: the controversy continues. J Am Coll Cardiol 1998; 31: 964–6

    Google Scholar 

  48. Antman EM, McCabe CH, Gurfinkel EP, et al. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) 11B Trial. Circulation 1999; 100: 1593–601

    Article  PubMed  CAS  Google Scholar 

  49. Antman EM, Cohen M, Radley D, et al. Assessment of the treatment effect of enoxaparin for unstable angina/non-Q-wave myocardial infarction. TIMI 11B-ESSENCE Meta-Analysis. Circulation 1999; 100: 1602–8

    Article  PubMed  CAS  Google Scholar 

  50. Cohen M, Demers C, Gurfinkel EP, et al. A comparison of lowmolecular-weight heparin with unfractionated heparin for unstable coronary artery disease. N Engl J Med 1997; 337: 447–52

    Article  PubMed  CAS  Google Scholar 

  51. Gruppo Italiano per lo Studio della Streptochinasi nell’Infarto Miocardico (GISSI). Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet 1986; I: 397–402

    Google Scholar 

  52. Wilcox RG, Olsson CG, Skene AM, et al. Trial of tissue plasminogen activator for mortality reduction in acute myocardial infarction. Anglo-Scandinavian Study of Early Thrombolysis (ASSET). Lancet 1988; II: 525–30

    Article  Google Scholar 

  53. AIMS Trial Study Group. Effect of intravenous APSAC on mortality after acute myocardial infarction: preliminary report of a placebo-controlled clinical trial. Lancet 1988; I: 545–9

    Google Scholar 

  54. AIMS Trial Study Group. Long-term effects of intravenous anistreplase in acute myocardial infarction: final report of the AIMS study. Lancet 1990; 335: 427–31

    Article  Google Scholar 

  55. Gruppo Italiano Per Lo Studio Della Streptochinasi Nell’ Infarto Miocardico (GISSI).: Long-term effects of intravenous thrombolysis in acute myocardial infarction: final report of the GISSI study. Lancet 1987; II: 871–4

    Google Scholar 

  56. Wilcox RG, von der Lippe G, Olsson CG, et al. Effects of alteplase in acute myocardial infarction: 6-month results from the ASSET Study. Lancet 1990; 335: 1175–8

    PubMed  CAS  Google Scholar 

  57. Berger AK, Radford MJ, Wang Y, et al. Thrombolytic therapy in older patients. J Am Coll Cardiol 2000; 36: 366–74

    Article  PubMed  CAS  Google Scholar 

  58. Fibrinolytic Therapy Trialist’s (FTT) Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1,000 patients. Lancet 1994; 343: 311–22

    Google Scholar 

  59. Berger AK, Schulman KA, Gersh BJ, et al. Primary coronary angioplasty vs thrombolysis for the management of acute myocardial infarction in elderly patients. JAMA 1999; 282: 341–8

    Article  PubMed  CAS  Google Scholar 

  60. The GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993; (329): 673–82

    Google Scholar 

  61. Antman EM, Giugliano RP, Gibson CM, et al. Abciximab facilitates the rate and extent of thrombolysis. Results of the Thrombolysis in Myocardial Infarction (TIMI) 14 trial. The TIMI 14 Investigators. Circulation 1999; 99: 2720–32

    Article  PubMed  CAS  Google Scholar 

  62. Miller JM, Smalling R, Ohman EM, et al. Effectiveness of early coronary angioplasty and abciximab for failed thrombolysis (reteplase or alteplase) during acute myocardial infarction (results from the GUSTO-III Trial). Am J Cardiol 1999; 84: 779–94

    Article  PubMed  CAS  Google Scholar 

  63. The Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-Plus) Study Investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptors with tirofiban in unstable angina and non-Q-wave myocardial infarction. N Engl J Med 1998; 338: 1488–97

    Article  Google Scholar 

  64. The PURSUIT Trial Investigators. Inhibition of the platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. N Engl J Med 1998; 339: 436–43

    Article  Google Scholar 

  65. Yusuf S, Collins R, MacMahon S, et al. Effect of intravenous nitrates on mortality in acute myocardial infarction: an overview of the randomised trials. Lancet 1988; I: 1088–92

    Article  Google Scholar 

  66. Danahy DT, Aronow WS. Hemodynamics and antianginal effects of high dose oral isorbide dinitrate after chronic use. Circulation 1977; 56: 205–12

    Article  PubMed  CAS  Google Scholar 

  67. Schechter M, Hod H, Chouraqui P, et al. Magnesium therapy in acute myocardial infarction when patients are not candidates for thrombolytic therapy. Am J Cardiol 1995; 75: 321–3

    Article  Google Scholar 

  68. The MAGIC Steering Committee. Rationale and design of the Magnesium in Coronaries (MAGIC) study: a clinical trial to re-evaluate the efficacy of early administration of magnesium in acute myocardial infarction. Am Heart J 2000; 139: 10–4

    Google Scholar 

  69. Hine LK, Laird N, Hewitt P, et al. Meta-analytic evidence against prophylactic use of lidocaine in acute myocardial infarction. Arch Intern Med 1989; 149: 2694–8

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

No sources of funding were used in preparing this manuscript. The author has no potential conflict of interest relevant to the contents of this manuscript.

Author information

Authors and Affiliations

  1. Department of Geriatrics and Adult Development, Mount Sinai School of Medicine, New York, New York, USA

    Wilbert S. Aronow

Authors
  1. Wilbert S. Aronow
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Wilbert S. Aronow.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Aronow, W.S. Drug Treatment of Elderly Patients with Acute Myocardial Infarction. Drugs Aging 18, 807–818 (2001). https://doi.org/10.2165/00002512-200118110-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002512-200118110-00002

Keywords

Search

Navigation